Literature DB >> 17886299

Molecular consequences of dominant Bethlem myopathy collagen VI mutations.

Naomi L Baker1, Matthias Mörgelin, Rishika A Pace, Rachel A Peat, Naomi E Adams, R J McKinlay Gardner, Lewis P Rowland, Geoffrey Miller, Peter De Jonghe, Berten Ceulemans, Mark C Hannibal, Matthew Edwards, Elizabeth M Thompson, Richard Jacobson, Ros C M Quinlivan, Salim Aftimos, Andrew J Kornberg, Kathryn N North, John F Bateman, Shireen R Lamandé.   

Abstract

OBJECTIVE: Dominant mutations in the three collagen VI genes cause Bethlem myopathy, a disorder characterized by proximal muscle weakness and commonly contractures of the fingers, wrists, and ankles. Although more than 20 different dominant mutations have been identified in Bethlem myopathy patients, the biosynthetic consequences of only a subset of these have been studied, and in many cases, the pathogenic mechanisms remain unknown.
METHODS: We have screened fourteen Bethlem myopathy patients for collagen VI mutations and performed detailed analyses of collagen VI biosynthesis and intracellular and extracellular assembly.
RESULTS: Collagen VI abnormalities were identified in eight patients. One patient produced around half the normal amount of alpha1(VI) messenger RNA and reduced amounts of collagen VI protein. Two patients had a previously reported mutation causing skipping of COL6A1 exon 14, and three patients had novel mutations leading to in-frame deletions toward the N-terminal end of the triple-helical domain. These mutations have different and complex effects on collagen VI intracellular and extracellular assembly. Two patients had single amino acid substitutions in the A-domains of COL6A2 and COL6A3. Collagen VI intracellular and extracellular assembly was normal in one of these patients.
INTERPRETATION: The key to dissecting the pathogenic mechanisms of collagen VI mutations lies in detailed analysis of collagen VI biosynthesis and assembly. The majority of mutations result in secretion and deposition of structurally abnormal collagen VI. However, one A-domain mutation had no detectable effect on assembly, suggesting that it acts by compromising collagen VI interactions in the extracellular matrix of muscle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17886299     DOI: 10.1002/ana.21213

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

1.  Collagen VI microfibril formation is abolished by an {alpha}2(VI) von Willebrand factor type A domain mutation in a patient with Ullrich congenital muscular dystrophy.

Authors:  Leona D Tooley; Laura K Zamurs; Nicola Beecher; Naomi L Baker; Rachel A Peat; Naomi E Adams; John F Bateman; Kathryn N North; Clair Baldock; Shireen R Lamandé
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

2.  Structure of a collagen VI α3 chain VWA domain array: adaptability and functional implications of myopathy causing mutations.

Authors:  Herimela Solomon-Degefa; Jan M Gebauer; Cy M Jeffries; Carolin D Freiburg; Patrick Meckelburg; Louise E Bird; Ulrich Baumann; Dmitri I Svergun; Raymond J Owens; Jörn M Werner; Elmar Behrmann; Mats Paulsson; Raimund Wagener
Journal:  J Biol Chem       Date:  2020-07-21       Impact factor: 5.157

3.  COL4A1 mutations as a potential novel cause of autosomal dominant CAKUT in humans.

Authors:  Thomas M Kitzler; Ronen Schneider; Stefan Kohl; Caroline M Kolvenbach; Dervla M Connaughton; Rufeng Dai; Nina Mann; Makiko Nakayama; Amar J Majmundar; Chen-Han W Wu; Jameela A Kari; Sherif M El Desoky; Prabha Senguttuvan; Radovan Bogdanovic; Natasa Stajic; Zaheer Valivullah; Monkol Lek; Shrikant Mane; Richard P Lifton; Velibor Tasic; Shirlee Shril; Friedhelm Hildebrandt
Journal:  Hum Genet       Date:  2019-06-22       Impact factor: 4.132

4.  Recessive COL6A2 C-globular missense mutations in Ullrich congenital muscular dystrophy: role of the C2a splice variant.

Authors:  Rui-Zhu Zhang; Yaqun Zou; Te-Cheng Pan; Dessislava Markova; Andrzej Fertala; Ying Hu; Stefano Squarzoni; Umbertina Conti Reed; Suely K N Marie; Carsten G Bönnemann; Mon-Li Chu
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

Review 5.  The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy.

Authors:  Carsten G Bönnemann
Journal:  Handb Clin Neurol       Date:  2011

Review 6.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

7.  Aberrant mitochondria in a Bethlem myopathy patient with a homozygous amino acid substitution that destabilizes the collagen VI α2(VI) chain.

Authors:  Laura K Zamurs; Miguel A Idoate; Eric Hanssen; Asier Gomez-Ibañez; Pau Pastor; Shireen R Lamandé
Journal:  J Biol Chem       Date:  2014-12-22       Impact factor: 5.157

Review 8.  Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies.

Authors:  Paolo Bernardi; Paolo Bonaldo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

9.  Mosaicism for dominant collagen 6 mutations as a cause for intrafamilial phenotypic variability.

Authors:  Sandra Donkervoort; Ying Hu; Tanya Stojkovic; Nicol C Voermans; A Reghan Foley; Meganne E Leach; Jahannaz Dastgir; Véronique Bolduc; Thomas Cullup; Alix de Becdelièvre; Lin Yang; Hai Su; Katherine Meilleur; Alice B Schindler; Erik-Jan Kamsteeg; Pascale Richard; Russell J Butterfield; Thomas L Winder; Thomas O Crawford; Robert B Weiss; Francesco Muntoni; Valérie Allamand; Carsten G Bönnemann
Journal:  Hum Mutat       Date:  2015-01       Impact factor: 4.878

10.  Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies.

Authors:  Russell J Butterfield; A Reghan Foley; Jahannaz Dastgir; Stephanie Asman; Diane M Dunn; Yaqun Zou; Ying Hu; Sandra Donkervoort; Kevin M Flanigan; Kathryn J Swoboda; Thomas L Winder; Robert B Weiss; Carsten G Bönnemann
Journal:  Hum Mutat       Date:  2013-11       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.